6090.T

The company maintains a strong liquidity position, with cash and equivalents amounting to ¥1,562,417,000, representing 65.8% of total assets. The liquidity FPT score indicates a low liquidity risk, supported by a current ratio of 4.14 and a debt-to-equity ratio of 0.06, suggesting a conservative capital structure with minimal leverage.

Profitability metrics show a return on equity of 13.43% and a return on assets of 10.8%, both exceeding the industry median for biotechnology and medical research firms. The operating margin of 19.1% and net margin of 17.6% indicate strong cost control and pricing power, aligning with the industry's preferred metrics of gross margin and operating margin.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to regional economic or regulatory risks, though the exact geographic breakdown is not available in the provided data.

Growth trajectory is positive, with a current FY revenue of ¥1,455,004,000 and a free cash flow of ¥123,106,000. The operating cash flow of ¥373,531,000 supports reinvestment and dividend sustainability. The capital expenditure of -¥148,740,000 indicates a reduction in capital spending, which may signal a shift in strategic focus or a response to market conditions.

Risk factors are minimal, with no immediate filing-based liquidity or dilution flags detected. The dilution potential is low, and the company has not issued additional shares recently. The absence of significant debt and the high cash reserves further reduce financial risk.

Recent events include the latest actual EPS of 43.67 JPY and revenue of ¥1,455,000,000, aligning with analyst estimates. No recent filings or transcripts indicate material changes in business operations or strategic direction.